Search

Eva Hadaschik

Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
Characterisation and outcome of RAC1 mutated melanoma

Published with Wowchemy — the free, open source website builder that empowers creators.